Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Oct 2 - Oct 7
While initially introduced as a treatment for type-2 diabetes, patients taking glucagon-like peptide 1 (GLP-1) receptor agonists (see Text Box 1) found a discrete change in the amount and types of food they desire, including the curbing of cravings for certain less nutritious categories of foods (e.g., sweets, fried foods), which helped patients who were overweight or obese lose clinically significant amounts of weight and, with continued use, to maintain weights 15%20% lower than premedication levels (Rubino et al., 2021, Aronne et al., 2024)
Its the patient who feels great at week six and decides to push the dose higher than the protocol calls for without telling me
The results are in the chart(s) that follow
Chronic Psychological Stress Accelerates Vascular Senescence and Impairs Ischemia-Induced Neovascularization: The Role of Dipeptidyl Peptidase-4/Glucagon-Like Peptide-1-Adiponectin Axis
